Country: Canada
Language: English
Source: Health Canada
BUDESONIDE
TILLOTTS PHARMA GMBH
A07EA06
BUDESONIDE
2.3MG
ENEMA
BUDESONIDE 2.3MG
RECTAL
7 TABLETS, 7 SOLUTIONS
Prescription
ANTI-INFLAMMATORY AGENTS
Active ingredient group (AIG) number: 0116807015; AHFS:
APPROVED
2016-07-13
_ENTOCORT_ _®_ _ ENEMA (Budesonide dispersible tablets) _ _Page 1 of 26_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR ENTOCORT® ENEMA Budesonide dispersible tablets Enema, 0.02 mg/mL budesonide (when reconstituted), Rectal use Glucocorticosteroid Enema Tillotts Pharma GmbH Warmbacher Strasse 80 79618 Rheinfelden Germany Date of Initial Authorization: NOV 25, 1994 Date of Revision: MAR 31, 2023 Importer/Distributor: C.R.I. Burlington, ON L7N 3G2 Control Number: 268828 _ _ _ENTOCORT_ _®_ _ ENEMA (Budesonide dispersible tablets) _ _Page 2 of 26_ RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS, Hypersensitivity 03/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES ............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4 1 INDICATIONS ............................................................................................................... 4 1.1 Pediatrics ................................................................................................................ 4 1.2 Geriatrics ................................................................................................................ 4 2 CONTRAINDICATIONS ................................................................................................. 4 4 DOSAGE AND ADMINISTRATION ................................................................................. 4 4.1 Dosing Considerations ............................................................................................ 4 4.2 Recommended Dose and Dosage Adjustment ....................................................... 4 4.3 Reconstitution ............................................................ Read the complete document